Breaking News Instant updates and real-time market news.

2020-12-11 07:04:47 XOM Exxon Mobil $44.01 / +1.22 (+2.85%) 07:04 12/11/20 12/11 07:04 12/11/20 07:04	Exxon Mobil discovers hydrocarbons at Sloanea-1 exploration well ExxonMobil and Petronas have discovered hydrocarbons at the Sloanea-1 exploration well on Block 52 offshore Suriname, adding to ExxonMobil's extensive finds in the Guyana-Suriname basin. The well was drilled by operator Petronas, and the discovery is being evaluated to determine its resource potential. ExxonMobil said in November that it is prioritizing near-term capital spending on advantaged assets with the highest potential future value. Petronas drilled the well to a total depth of approximately 15,682 feet using the Maersk Developer rig. Block 52 covers an area of 1.2M acres and is located approximately 75 miles offshore north of Suriname's capital city, Paramaribo. The water depths on Block 52 range from 160 to 3,600 feet. ExxonMobil Exploration and Production Suriname B.V., an affiliate of ExxonMobil, holds 50% interest in Block 52. Petronas Suriname E&P B.V., a subsidiary of Petronas, is operator and holds 50% interest.
XOM Exxon Mobil $44.01 / +1.22 (+2.85%) 12/09/20 Citi Exxon Mobil price target raised to $39 from $33 at Citi 12/09/20 Citi Exxon Mobil price target raised to $39 from $33 at Citi 11/16/20 Truist Exxon Mobil price target raised to $39 from $36 at Truist 11/02/20 Credit Suisse Exxon Mobil price target lowered to $37 from $47 at Credit Suisse

2020-12-11 07:04:47

XOM

Exxon Mobil

$44.01 / +1.22 (+2.85%)

07:04

12/11/20

12/11

07:04

12/11/20

07:04

Exxon Mobil discovers hydrocarbons at Sloanea-1 exploration well

ExxonMobil and Petronas have discovered hydrocarbons at the Sloanea-1 exploration well on Block 52 offshore Suriname, adding to ExxonMobil's extensive finds in the Guyana-Suriname basin. The well was drilled by operator Petronas, and the discovery is being evaluated to determine its resource potential. ExxonMobil said in November that it is prioritizing near-term capital spending on advantaged assets with the highest potential future value. Petronas drilled the well to a total depth of approximately 15,682 feet using the Maersk Developer rig. Block 52 covers an area of 1.2M acres and is located approximately 75 miles offshore north of Suriname's capital city, Paramaribo. The water depths on Block 52 range from 160 to 3,600 feet. ExxonMobil Exploration and Production Suriname B.V., an affiliate of ExxonMobil, holds 50% interest in Block 52. Petronas Suriname E&P B.V., a subsidiary of Petronas, is operator and holds 50% interest.

XOM Exxon Mobil

$44.01 / +1.22 (+2.85%)

12/09/20 Citi: Exxon Mobil price target raised to $39 from $33 at Citi

12/09/20 Citi: Exxon Mobil price target raised to $39 from $33 at Citi

11/16/20 Truist: Exxon Mobil price target raised to $39 from $36 at Truist

11/02/20 Credit Suisse: Exxon Mobil price target lowered to $37 from $47 at Credit Suisse

TODAY'S FREE FLY STORIES

Earnings	M&T Bank reports Q4 EPS $3.54, consensus $3.03 » 05:45 01/21/21 01/21 05:45 01/21/21 05:45 MTB M&T Bank $143.99 / -2.12 (-1.45%) Reports Q4 CET1 capital… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals Events MTB M&T Bank $143.99 / -2.12 (-1.45%) 01/20/21 M&T Bank announces $800M share repurchase program 11/16/20 Berkshire Hathaway exits Costco position, reduces stake in Wells Fargo 08/14/20 Berkshire Hathaway takes stake in Barrick Gold, exits multiple airline stocks 07/30/20 M&T Bank appoints Francesco Lagutaine Chief Marketing and Communications Officer MTB M&T Bank $143.99 / -2.12 (-1.45%) 01/07/21 BofA M&T Bank upgraded to Buy from Neutral at BofA 01/06/21 Deutsche Bank M&T Bank price target raised to $155 from $135 at Deutsche Bank 01/04/21 Barclays M&T Bank price target raised to $163 from $159 at Barclays 10/08/20 Wolfe Research M&T Bank downgraded to Underperform from Peer Perform at Wolfe Research MTB M&T Bank $143.99 / -2.12 (-1.45%) 10/22/20 M&T Bank reports Q3 EPS $2.75, consensus $2.60 07/23/20 M&T Bank reports Q2 EPS $1.76, consensus $1.65 MTB M&T Bank $143.99 / -2.12 (-1.45%) 08/15/20 PNC, KeyCorp among large regional banks offering steady dividends, Barron's says 11:00 Today M&T Bank - MTB
Hot Stocks	Roche announces FDA acceptance of Genentech Esbriet sNDA » 05:35 01/21/21 01/21 05:35 01/21/21 05:35 RHHBY Roche $0.00 / + (+0.00%) Genentech, a member of… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events RHHBY Roche $0.00 / + (+0.00%) 01/12/21 Roche confirms U.S to buy additional doses of Regeneron's Cov-19 cocktail 01/07/21 Roche granted FDA orphan drug status for Atezolizumab in esophageal cancer 01/06/21 Pluristem appoints Maital Shemesh-Rasmussen, Rami Levi to board 01/05/21 Genentech announces tiragolumab granted Breakthrough Therapy Designation by FDA RHHBY Roche $0.00 / + (+0.00%) 01/15/21 Deutsche Bank Roche initiated with a Hold at Deutsche Bank 01/12/21 UBS Roche price target lowered to CHF 355 from CHF 365 at UBS 01/11/21 Berenberg Roche price target lowered to CHF 325 from CHF 350 at Berenberg 01/11/21 Benchmark Phesgo EU approval/Horizon deal fuel Halozyme increased guidance, says Benchmark RHHBY Roche $0.00 / + (+0.00%) 10/27/20 Oncolytics announces new GI cancer study using 10/15/20 Roche confirms outlook for 2020 based on assessment of COVID-19 10/15/20 Roche reports 9 months group sales CHF43.98B vs. CHF46.07B last year 09/11/20 Genentech: data shows Ocrevus 'highly effective' treatment option in RRMS RHHBY Roche $0.00 / + (+0.00%) 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports 11/17/20 Regeneron says Roche completed early tests to make COVID drug, Reuters says RHHBY Roche $0.00 / + (+0.00%) 12/26/20 Week in review: How Trump's policies moved stocks 11/30/20 Fly Intel: Wall Street's top stories for Monday 11/30/20 Fly Intel: Wall Street's top stories at midday 11/21/20 Week in review: How Trump's policies moved stocks 01/28/21 IASLC Virtual World Conference on Lung Cancer 03/02/21 2021 London Global Healthcare Virtual Conference 02/04/21 Roche - RHHBY
Hot Stocks	Addex Therapeutics receives IND approval to start study in epilepsy » 05:33 01/21/21 01/21 05:33 01/21/21 05:33 ADXN Addex Therapeutics $10.49 / +0.04 (+0.38%) , JNJ Johnson & Johnson $162.30 / -0.45 (-0.28%) Addex Therapeutics (ADXN)… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options JNJ JNJ Johnson & Johnson $162.30 / -0.45 (-0.28%) 01/19/21 Royalty Pharma acquires royalty interest in Seltorexant from Minerva 01/19/21 Minerva, Royalty Pharma announce sale of seltorexant royalty for up to $155M 01/15/21 Halozyme says Janssen receives FDA approval of Darzalex Faspro 01/15/21 Genmab says Janssen granted FDA approval for Darzalez Faspro ADXN JNJ ADXN Addex Therapeutics $10.49 / +0.04 (+0.38%) JNJ Johnson & Johnson $162.30 / -0.45 (-0.28%) 01/15/21 B. Riley Securities Arcturus Therapeutics downgraded to Neutral from Buy at B. Riley Securities 01/14/21 Morgan Stanley 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley 01/14/21 Oppenheimer Essa Pharma price target raised to $20 from $9 at Oppenheimer 12/29/20 Piper Sandler Piper still believes in Arcturus vaccine after 'underwhelming' immunogenicity JNJ JNJ Johnson & Johnson $162.30 / -0.45 (-0.28%) 10/13/20 Johnson & Johnson sees 'robutst, double-digit sales growth' in 2021 10/13/20 Johnson & Johnson sees Q4 sales 'around' 2019 levels, consensus $21.52B 10/13/20 Johnson & Johnson raises FY20 adj. EPS view to $7.95-$8.05 from $7.75-$7.95 10/13/20 Johnson & Johnson reports Q3 adj. EPS $2.20, consensus $1.98 JNJ JNJ Johnson & Johnson $162.30 / -0.45 (-0.28%) 01/13/21 Johnson & Johnson's one-dose COVID-19 vaccine appears 'promising,' CNBC says 01/13/21 J&J chief science officer sees possible vaccine approval by March, Reuters says 01/13/21 J&J sees U.S. decision on COVID-19 vaccine candidate by March, Bloomberg says 01/13/21 EU lawmaker says J&J likely to submit vaccine approval in Feb., Reuters reports JNJ JNJ Johnson & Johnson $162.30 / -0.45 (-0.28%) 01/14/21 Fly Intel: Wall Street's top stories for Thursday 01/14/21 Fly Intel: Wall Street's top stories at midday 01/13/21 Fly Intel: Wall Street's top stories for Wednesday 12/29/20 Street Fight: Citi sees opportunity in Arcturus as COVID data prompts downgrades 01/26/21 Johnson & Johnson - JNJ JNJ JNJ Johnson & Johnson $162.30 / -0.45 (-0.28%) 12/01/20 Johnson & Johnson call volume above normal and directionally bullish 10/13/20 Unusually active option classes on open October 13th 09/23/20 Unusually active option classes on open September 23rd 08/24/20 Unusually active option classes on open August 24th
Hot Stocks	Galapagos announces NICE recommendation for Jyseleca on NHS » 05:27 01/21/21 01/21 05:27 01/21/21 05:27 GLPG Galapagos $108.63 / +0.89 (+0.83%) Galapagos announced that… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events GLPG Galapagos $108.63 / +0.89 (+0.83%) 12/15/20 Galapagos to assume development, manufacturing, other rights for Jyseleca 12/15/20 Gilead will not pursue FDA approval of Jyseleca for RA 12/01/20 Galapagos announces 1st dosing in Mangrove trial in GLPG2737 with ADPKD patient 11/30/20 Galapagos presents results with GLPG1205 in IPF patients in Pinta trial GLPG Galapagos $108.63 / +0.89 (+0.83%) 01/19/21 Barclays Galapagos price target raised to $125 from $85.50 at Barclays 01/19/21 Morgan Stanley Galapagos upgraded to Overweight from Equal Weight at Morgan Stanley 12/18/20 Truist Gilead price target lowered to $62 from $67 at Truist 12/17/20 Maxim Galapagos price target lowered to $140 from $170 at Maxim GLPG Galapagos $108.63 / +0.89 (+0.83%) 08/06/20 Galapagos reports first half EPS EUR (2.55) vs. (1.76) last year GLPG Galapagos $108.63 / +0.89 (+0.83%) 12/16/20 Fly Intel: Wall Street's top stories for Wednesday 12/16/20 Fly Intel: Wall Street's top stories at midday 12/15/20 Fly Intel: After-Hours Movers 08/19/20 Fly Intel: Wall Street's top stories for Wednesday 03/02/21 2021 London Global Healthcare Virtual Conference
Recommendations	Pinnacle Financial price target raised to $80 from $60 at Keefe Bruyette » 05:27 01/21/21 01/21 05:27 01/21/21 05:27 PNFP Pinnacle Financial $72.53 / +2.21 (+3.14%) Keefe Bruyette analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events PNFP Pinnacle Financial $72.53 / +2.21 (+3.14%) 10/20/20 Pinnacle Financial declares16c per share quarterly cash dividend PNFP Pinnacle Financial $72.53 / +2.21 (+3.14%) 01/04/21 Wells Fargo Pinnacle Financial downgraded to Equal Weight from Overweight at Wells Fargo 12/15/20 JPMorgan Pinnacle Financial upgraded to Overweight from Neutral at JPMorgan 11/16/20 Stephens Pinnacle Financial resumed with an Overweight at Stephens 09/29/20 Truist Truist raises price targets on select regional banks PNFP Pinnacle Financial $72.53 / +2.21 (+3.14%) 01/19/21 Pinnacle Financial reports Q4 EPS $1.58 ex-items, consensus $1.35 01/19/21 Pinnacle Financial reports Q4 EPS $1.58 ex-items, consensus $1.35 01/19/21 Notable companies reporting after market close 10/20/20 Pinnacle Financial reports Q3 EPS $1.42, consensus $1.09 03/11/21 Virtual Atlanta and Texas Bank Summit

Upgrade	Barings BDC upgraded to Buy from Hold at Jefferies » 05:25 01/21/21 01/21 05:25 01/21/21 05:25 BBDC Barings BDC $9.08 / -0.025 (-0.27%) Jefferies analyst Kyle… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings BBDC Barings BDC $9.08 / -0.025 (-0.27%) 11/09/20 Barings BDC raises dividend to 17c from 16c 08/10/20 MVC Capital to merge into Barings BDC BBDC Barings BDC $9.08 / -0.025 (-0.27%) 08/18/20 Fly Intel: Top five analyst upgrades 08/17/20 Keefe Bruyette Barings BDC upgraded to Outperform from Market Perform at Keefe Bruyette 06/24/20 Raymond James Barings BDC upgraded to Strong Buy from Outperform at Raymond James 06/24/20 Raymond James Barings BDC upgraded to Strong Buy from Outperform at Raymond James BBDC Barings BDC $9.08 / -0.025 (-0.27%) 11/09/20 Barings BDC reports Q3 EPS 17c, consensus 15c 08/05/20 Barings BDC reports Q2 NII 14c, consensus 15c
Upgrade	Freshpet upgraded to Outperform from Perform at Oppenheimer » 05:25 01/21/21 01/21 05:25 01/21/21 05:25 FRPT Freshpet $146.47 / +2.39 (+1.66%) Oppenheimer analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly FRPT Freshpet $146.47 / +2.39 (+1.66%) 09/24/20 Freshpet completes CFO transition with appointment of Heather Pomerantz 08/31/20 Freshpet CFO Kassar sells 10,000 common shares 08/14/20 Freshpet launches multi-year corporate governance plan 08/03/20 Freshpet appoints Thembi Machaba as SVP, human resources FRPT Freshpet $146.47 / +2.39 (+1.66%) 01/19/21 Stephens Freshpet initiated with an Overweight at Stephens 01/19/21 JPMorgan Freshpet price target raised to $170 from $160 at JPMorgan 01/14/21 Truist Freshpet price target raised to $140 from $120 at Truist 01/11/21 Stifel Freshpet price target raised to $160 from $120 at Stifel FRPT Freshpet $146.47 / +2.39 (+1.66%) 01/13/21 Freshpet sees Q4 revenue $84.5M, consensus $88.41M 01/13/21 Freshpet sees Q4 net sales $84.5M, consensus $88.41M 01/13/21 Freshpet sees FY20 net sales $318.8M, consensus $322.73M 11/02/20 Freshpet backs FY20 revenue view $320M, consensus $321.89M 27 Feb FRPT Freshpet $146.47 / +2.39 (+1.66%) 11/02/20 Fly Intel: After-Hours Movers 08/03/20 Fly Intel: After-Hours Movers
Downgrade	Equinor downgraded to Hold from Buy at Santander » 05:24 01/21/21 01/21 05:24 01/21/21 05:24 EQNR Equinor $19.67 / -0.14 (-0.71%) Santander analyst Jason… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Events EQNR Equinor $19.67 / -0.14 (-0.71%) 12/15/20 KNOT Offshore Partners announces acquisition of Tove Knutsen shuttle tanker 11/18/20 Norsk Hydro, Panasonic and Equinor sign MOU to explore European battery business 10/19/20 TechnipFMC awarded EPC contract by Equinor for Breidablikk Pipelay 10/14/20 Equinor, Microsoft sign MoU to collaborate on Northern Lights project EQNR Equinor $19.67 / -0.14 (-0.71%) 01/15/21 JPMorgan Equinor price target raised to NOK 190 from NOK 180 at JPMorgan 01/14/21 Societe Generale Societe Generale downgrades three EU oil & gas names after strong performances 01/14/21 Societe Generale Equinor downgraded to Hold from Buy at Societe Generale 01/13/21 Credit Suisse Equinor price target raised to NOK 220 from NOK 205 at Credit Suisse 03/01/21 26th Annual Energy Virtual Summit
Hot Stocks	Calliditas Therapeutics announces full enrollment of NefIgArd trial » 05:23 01/21/21 01/21 05:23 01/21/21 05:23 CALT Calliditas Therapeutics $32.59 / +0.69 (+2.16%) Calliditas Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Syndicate CALT Calliditas Therapeutics $32.59 / +0.69 (+2.16%) 01/20/21 Calliditas Therapeutics to provide data from Part A of NefIgArd study 01/18/21 Calliditas says Phase 1 setanaxib trial shows favorable pharmacokinetic profile 11/09/20 Calliditas Therapeutics says Part A of NefIgArd trial met its primary objective CALT Calliditas Therapeutics $32.59 / +0.69 (+2.16%) 07/01/20 Citi Calliditas Therapeutics initiated with a Buy at Citi 06/30/20 Jefferies Calliditas Therapeutics initiated with a Buy at Jefferies 06/30/20 Stifel Calliditas Therapeutics initiated with a Buy at Stifel 05 Jun
Upgrade	Voestalpine upgraded to Accumulate from Hold at Erste Group » 05:23 01/21/21 01/21 05:23 01/21/21 05:23 VLPNY Voestalpine $0.00 / + (+0.00%) Erste Group analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research VLPNY Voestalpine $0.00 / + (+0.00%) 01/19/21 Morgan Stanley Voestalpine price target raised to EUR 26 from EUR 25.40 at Morgan Stanley 01/18/21 Credit Suisse Voestalpine upgraded to Neutral from Underperform at Credit Suisse 11/25/20 Deutsche Bank Voestalpine downgraded to Hold from Buy at Deutsche Bank 11/17/20 Morgan Stanley Voestalpine price target raised to EUR 18.50 from EUR 18 at Morgan Stanley

Upgrade	Palfinger upgraded to Accumulate from Hold at Erste Group » 05:22 01/21/21 01/21 05:22 01/21/21 05:22 PLFRY Palfinger $0.00 / + (+0.00%) Erste Group analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research PLFRY Palfinger $0.00 / + (+0.00%) 05/06/20 Berenberg Palfinger price target lowered to EUR 22 from EUR 23 at Berenberg 05/06/20 Kepler Cheuvreux Palfinger upgraded to Hold from Reduce at Kepler Cheuvreux
Upgrade	Grupo Mexico upgraded to Outperform from Underperform at Itau BBA » 05:22 01/21/21 01/21 05:22 01/21/21 05:22 GMBXF Grupo Mexico $0.00 / + (+0.00%) Itau BBA analyst Daniel… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research GMBXF Grupo Mexico $0.00 / + (+0.00%) 01/06/21 Barclays Grupo Mexico initiated with an Equal Weight at Barclays 06/16/20 Goldman Sachs Southern Copper downgraded to Neutral from Buy at Goldman Sachs 06/08/20 Citi Grupo Mexico downgraded to Neutral from Buy at Citi 03/25/20 Morgan Stanley Grupo Mexico upgraded to Overweight from Equal Weight at Morgan Stanley
Earnings	TAL Education sees Q4 revenue $1.18B-$1.2B, consensus $1.17B » 05:21 01/21/21 01/21 05:21 01/21/21 05:21 TAL TAL Education $67.73 / -0.6 (-0.88%) Based on our current… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals Events Options TAL TAL Education $67.73 / -0.6 (-0.88%) 12/28/20 TAL Education announces $3.3B private placement with Silver Lake-led investors TAL TAL Education $67.73 / -0.6 (-0.88%) 12/30/20 Credit Suisse Credit Suisse cuts TAL target to $79 on margin pressure from online competition 12/29/20 CLSA TAL Education now has 'war chest' to fight competition, says CLSA 11/25/20 Morgan Stanley OneSmart downgraded to Equal Weight on margin pressure at Morgan Stanley 10/26/20 JPMorgan TAL Education downgraded to Neutral from Overweight at JPMorgan (Friday) TAL TAL Education $67.73 / -0.6 (-0.88%) 05:19 Today TAL Education reports Q3 EPS 2c, consensus 7c 10/22/20 TAL Education sees Q3 revenue $1.06B-$1.09B, consensus $1.14B 10/22/20 TAL Education reports Q2 EPS 8c, consensus 12c 07/30/20 TAL Education sees Q2 revenue $1.08B-$1.11B, consensus $1.24B TAL TAL Education $67.73 / -0.6 (-0.88%) 08/07/20 Citon says authorities given info to end GSX Techedu 'charade' 08:00 Today TAL Education - TAL TAL TAL Education $67.73 / -0.6 (-0.88%) 09/03/20 Tal Education Group put volume heavy and directionally bearish
Initiation	Cyrela Brazil Realty initiated with a Buy at BTG Pactual » 05:21 01/21/21 01/21 05:21 01/21/21 05:21 CYRBY Cyrela Brazil Realty $0.00 / + (+0.00%) BTG Pactual initiated… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research CYRBY Cyrela Brazil Realty $0.00 / + (+0.00%) 08/28/20 JPMorgan Cyrela Brazil Realty upgraded to Overweight from Neutral at JPMorgan
Downgrade	Incitec Pivot downgraded to Neutral from Outperform at Credit Suisse » 05:20 01/21/21 01/21 05:20 01/21/21 05:20 INCZY Incitec Pivot $0.00 / + (+0.00%) Credit Suisse analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research INCZY Incitec Pivot $0.00 / + (+0.00%) 08/06/20 Goldman Sachs Incitec Pivot upgraded to Buy from Neutral at Goldman Sachs 04/22/20 JPMorgan Incitec Pivot upgraded to Overweight from Neutral at JPMorgan

Earnings	TAL Education reports Q3 EPS 2c, consensus 7c » 05:19 01/21/21 01/21 05:19 01/21/21 05:19 TAL TAL Education $67.73 / -0.6 (-0.88%) Reports Q3 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals Events Options TAL TAL Education $67.73 / -0.6 (-0.88%) 12/28/20 TAL Education announces $3.3B private placement with Silver Lake-led investors TAL TAL Education $67.73 / -0.6 (-0.88%) 12/30/20 Credit Suisse Credit Suisse cuts TAL target to $79 on margin pressure from online competition 12/29/20 CLSA TAL Education now has 'war chest' to fight competition, says CLSA 11/25/20 Morgan Stanley OneSmart downgraded to Equal Weight on margin pressure at Morgan Stanley 10/26/20 JPMorgan TAL Education downgraded to Neutral from Overweight at JPMorgan (Friday) TAL TAL Education $67.73 / -0.6 (-0.88%) 10/22/20 TAL Education sees Q3 revenue $1.06B-$1.09B, consensus $1.14B 10/22/20 TAL Education reports Q2 EPS 8c, consensus 12c 07/30/20 TAL Education sees Q2 revenue $1.08B-$1.11B, consensus $1.24B 07/30/20 TAL Education reports Q1 EPS 18c, consensus 1c TAL TAL Education $67.73 / -0.6 (-0.88%) 08/07/20 Citon says authorities given info to end GSX Techedu 'charade' 08:00 Today TAL Education - TAL TAL TAL Education $67.73 / -0.6 (-0.88%) 09/03/20 Tal Education Group put volume heavy and directionally bearish
Upgrade	Nordic Entertainment upgraded to Buy from Hold at Nordea » 05:19 01/21/21 01/21 05:19 01/21/21 05:19 NENTF Nordic Entertainment $0.00 / + (+0.00%) Nordea analyst Klas… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research NENTF Nordic Entertainment $0.00 / + (+0.00%) 12/04/20 Morgan Stanley Nordic Entertainment upgraded to Overweight from Equal Weight at Morgan Stanley 11/18/20 Berenberg Nordic Entertainment initiated with a Buy at Berenberg 05/18/20 Morgan Stanley Nordic Entertainment price target lowered to SEK 230 at Morgan Stanley
Downgrade	Fluidra downgraded to Hold from Buy at Santander » 05:18 01/21/21 01/21 05:18 01/21/21 05:18 FLUIF Fluidra $0.00 / + (+0.00%) Santander analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research FLUIF Fluidra $0.00 / + (+0.00%) 01/08/21 Berenberg Fluidra price target raised to EUR 22 from EUR 18 at Berenberg 12/03/20 HSBC Fluidra downgraded to Hold from Buy at HSBC 10/30/20 Berenberg Fluidra price target raised to EUR 18 from EUR 17.50 at Berenberg 10/29/20 JPMorgan Fluidra price target raised to EUR 17 from EUR 16 at JPMorgan
Upgrade	Ternium upgraded to Outperform from Neutral at Bradesco BBI » 05:17 01/21/21 01/21 05:17 01/21/21 05:17 TX Ternium $30.26 / -0.06 (-0.20%) Bradesco BBI analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly TX Ternium $30.26 / -0.06 (-0.20%) 10/13/20 Ternium falls -11.5% TX Ternium $30.26 / -0.06 (-0.20%) 11/24/20 UBS Ternium upgraded to Neutral from Sell at UBS 11/06/20 Fly Intel: Top five analyst upgrades 11/06/20 JPMorgan Ternium upgraded to Overweight on steel recovery at JPMorgan 11/06/20 JPMorgan Ternium upgraded to Overweight from Neutral at JPMorgan TX Ternium $30.26 / -0.06 (-0.20%) 11/03/20 Ternium sees Q4 EBITDA up from Q3 11/03/20 Ternium reports Q3 EPS 74c, consensus 26c TX Ternium $30.26 / -0.06 (-0.20%) 11/03/20 Fly Intel: After-Hours Movers
Upgrade	Usiminas upgraded to Outperform from Neutral at Bradesco BBI » 05:17 01/21/21 01/21 05:17 01/21/21 05:17 USNZY Usiminas $0.00 / + (+0.00%) Bradesco BBI analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research USNZY Usiminas $0.00 / + (+0.00%) 09/17/20 Credit Suisse Usiminas upgraded to Neutral from Underperform at Credit Suisse 09/02/20 JPMorgan Usiminas upgraded to Overweight from Neutral at JPMorgan 07/24/20 Itau BBA Usiminas upgraded to Outperform from Market Perform at Itau BBA 06/19/20 Bradesco BBI Usiminas upgraded to Neutral from Underperform at Bradesco BBI

Upgrade	Skandinaviska Enskilda upgraded to Hold from Reduce at Kepler Cheuvreux » 05:16 01/21/21 01/21 05:16 01/21/21 05:16 SVKEF Skandinaviska Enskilda $0.00 / + (+0.00%) Kepler Cheuvreux analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research SVKEF Skandinaviska Enskilda $0.00 / + (+0.00%) 01/11/21 UBS Skandinaviska Enskilda price target raised to SEK 91 from SEK 85 at UBS 01/07/21 Credit Suisse Skandinaviska Enskilda downgraded to Underperform from Neutral at Credit Suisse 01/07/21 Credit Suisse Skandinaviska Enskilda downgraded to Underperform from Neutral at Credit Suisse 11/19/20 AlphaValue Skandinaviska Enskilda upgraded to Reduce from Sell at AlphaValue
Downgrade	Pearson downgraded to Neutral from Outperform at Exane BNP Paribas » 05:14 01/21/21 01/21 05:14 01/21/21 05:14 PSO Pearson $10.04 / +0.79 (+8.54%) Exane BNP Paribas analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings PSO Pearson $10.04 / +0.79 (+8.54%) 12/02/20 Pearson announces Mike Howells as new Chief Strategy Officer 10/14/20 Pearson 'on track' to deliver 2020 outturn in line with expectations 08/24/20 Pearson names Disney executive Andy Bird as new CEO, effective October 19 PSO Pearson $10.04 / +0.79 (+8.54%) 01/12/21 Berenberg Pearson price target raised to 475 GBp from 450 GBp at Berenberg 12/17/20 UBS Pearson price target raised to 750 GBp from 650 GBp at UBS 12/09/20 Fly Intel: Top five analyst downgrades 12/09/20 Kepler Cheuvreux Pearson cut to Reduce at Kepler Cheuvreux after recent share price rally PSO Pearson $10.04 / +0.79 (+8.54%) 10/14/20 Pearson reports Q3 revenue down 10% y/y vs. down 28% in Q2 07/24/20 Pearson reports 1H EPS 6.3p versus 6.1p in 1H19
Hot Stocks	Silvercorp Metals to acquire exploration rights to Zhonghe Project for $76M » 05:13 01/21/21 01/21 05:13 01/21/21 05:13 SVM Silvercorp Metals $6.14 / +0.33 (+5.68%) Silvercorp Metals… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Options SVM Silvercorp Metals $6.14 / +0.33 (+5.68%) 01/15/21 Silvercorp Metals reports production of ~900 ounces of gold in Q3 08/31/20 Silvercorp reports 18% increase in measured and indicated silver resources 07/28/20 Avalon Investment Holdings announce $4.5M investment of Silvercorp Metals SVM Silvercorp Metals $6.14 / +0.33 (+5.68%) 09/14/20 Canaccord Silvercorp Metals initiated with a Hold at Canaccord 09/01/20 BMO Capital Silvercorp Metals price target raised to C$10.50 from C$8.25 at BMO Capital 08/28/20 PI Financial Silvercorp Metals price target raised to C$10 from C$9 at PI Financial 08/10/20 BMO Capital Silvercorp Metals price target raised to C$8.25 from C$6.75 at BMO Capital SVM Silvercorp Metals $6.14 / +0.33 (+5.68%) 11/16/20 Sixteen new option listings and one option delisting on November 16th
Upgrade	ASML upgraded to Buy from Neutral at New Street » 05:13 01/21/21 01/21 05:13 01/21/21 05:13 ASML ASML $549.78 / +0.02 (+0.00%) New Street Research… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research Earnings Periodicals Events ASML ASML $549.78 / +0.02 (+0.00%) 01/19/21 Barclays ASML price target raised to EUR 525 from EUR 475 at Barclays 01/15/21 JPMorgan ASML price target raised to EUR 437 from EUR 408 at JPMorgan 01/14/21 Barclays ASML price target raised to EUR 475 from EUR 425 at Barclays 01/13/21 UBS ASML price target raised to EUR 430 from EUR 395 at UBS ASML ASML $549.78 / +0.02 (+0.00%) 01/20/21 ASML sees Q1 net sales EUR 3.9B-EUR 4.1B, gross margin 50%-51% 01/20/21 ASML reports Q4 EPS EUR 3.23 vs. EUR 2.54 last quarter 10/14/20 ASML sees Q4 revenue EUR3.6B-EUR3.8B 10/14/20 ASML reports Q3 EPS EUR2.54 vs. EUR1.79 last quarter ASML ASML $549.78 / +0.02 (+0.00%) 11/13/20 TSMC places EUV equipment orders with ASML for 2021, DigiTimes reports 02/11/21 Technology & Internet Virtual Conference 01/26/21 ASML 01/27/21 ASML
Downgrade	Corteva downgraded to Neutral from Buy at Redburn » 05:12 01/21/21 01/21 05:12 01/21/21 05:12 CTVA Corteva $43.67 / +0.15 (+0.34%) Redburn analyst Tony… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals Events CTVA Corteva $43.67 / +0.15 (+0.34%) 01/19/21 Matrix Service subsidiary awarded construction of water facility by Corteva 01/04/21 Corteva welcomes new Chief Technology Officer Sam Eathington 12/23/20 Tyson Foods appoints Megan Britt as VP, investor relations 11/13/20 Starboard Value takes Corteva stake, exits eBay CTVA Corteva $43.67 / +0.15 (+0.34%) 01/19/21 Deutsche Bank Corteva named 'Catalyst Call: Buy Idea' at Deutsche Bank 01/08/21 Deutsche Bank Corteva price target raised to $50 from $40 at Deutsche Bank 12/18/20 Susquehanna Corteva downgraded to Neutral from Positive at Susquehanna 12/14/20 Morgan Stanley Morgan Stanley upgrades Corteva, points to five reasons for above-consensus view CTVA Corteva $43.67 / +0.15 (+0.34%) 11/04/20 Corteva backs FY20 operating EPS view $1.25-$1.45, consensus $1.38 11/04/20 Corteva reports Q3 adjusted EPS (39c), consensus (42c) 11/04/20 Notable companies reporting after market close 08/05/20 Corteva sees FY20 operating EPS $1.25-$1.45, consensus $1.40 CTVA Corteva $43.67 / +0.15 (+0.34%) 11/19/20 Corteva board backs CEO amid pressure from Starboard, Reuters says 10/09/20 Starboard makes new bets on Corteva, ON Semiconductor, Reuters reports 02/04/21 Corteva - CTVA

Events

Earnings calls, analyst events, roadshows and more

SI
Today at 08:00

Silvergate Capital - SI Conference Calls
BEDU
Today at 08:00

Bright Scholar - BEDU Conference Calls
DFS
Today at 08:00

Discover - DFS Conference Calls
WNS
Today at 08:00

WNS Holdings - WNS Conference Calls
TAL
Today at 08:00

TAL Education - TAL Conference Calls
STL
Today at 08:00

Sterling Bancorp - STL Conference Calls
TFC
Today at 08:00

Truist Financial - TFC Conference Calls
CTXS
Today at 08:15

Citrix - CTXS Conference Calls
PLXS
Today at 08:30

Plexus - PLXS Conference Calls
UNP
Today at 08:45

Union Pacific - UNP Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	BDGE X BDGE Bridge Bancorp Block Trade Managers: Morgan Stanley Priced at: $25.50 700K Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TCRR X TCRR TCR2 Therapeutics Secondary Managers: Goldman Sachs, Jefferies, Piper Sandler & BMO Capital Priced at: $30.50 4.59M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ACRS X ACRS Aclaris Therapeutics Spot Secondary Managers: Cantor Fitzgerald & William Blair, H.C. Wainwright Priced at: $17.50 5.484M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ACRX X ACRX AcelRx Spot Secondary Managers: Cantor Fitzgerald Priced at: $1.90 14.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BLRX X BLRX BioLineRx Spot Secondary Managers: H.C. Wainwright Priced at: $2.40 12.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BNGO X BNGO Bionano Genomics Spot Secondary Managers: Oppenheimer, BTIG, Ladenburg, Maxim Priced at: $6.00 33.333M Shares DSS X DSS Document Security Spot Secondary Managers: Aegis Priced at: $3.60 6.67M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FULC X FULC Fulcrum Therapeutics Spot Secondary Managers: SVB Leerink, Piper Sandler & Credit Suisse Priced at: $11.00 4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LAC X LAC Lithium Americas Spot Secondary Managers: Canaccord, Deutsche Bank, Evercore ISI, Stifel Priced at: $22.00 15.9M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PERI X PERI Perion Network Spot Secondary Managers: Oppenheimer, Stifel, Roth Capital, LAKE Priced at: $11.50 4.99M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SYRS X SYRS Syros Pharmaceuticals Spot Secondary Managers: Cowen & Piper Sandler Priced at: $14.00 5.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	DFH X DFH Dream Finders Homes IPO Managers: BofA, RBC Capital & BTIG, Builder Advisor, Zelman, TCB Capital, Wedbush Priced at: $13.00 9.6M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MYTE X MYTE Mytheresa IPO Managers: Morgan Stanley & JPMorgan, Credit Suisse, UBS, Jefferies, Cowen Priced at: $26.00 15.647M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ATHA X ATHA Athira Pharma Secondary Managers: Goldman Sachs, Jefferies, Stifel & JMP Securities Priced at: $22.50 4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CMRX X CMRX Chimerix Secondary Managers: Jefferies & Cowen, H.C. Wainwright, JonesTrading Priced at: $8.50 11.765M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial DYN X DYN Dyne Therapeutics Secondary Managers: JPMorgan, Jefferies, Piper Sandler & Stifel Priced at: $28.00 6M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ORC X ORC Orchid Island Capital Spot Secondary Managers: JPMorgan Priced at: $5.30 7.6M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	No deals
Wed	RLX X RLX RLX Technology IPO Managers: Citi, China Renaissance $8.00-10.00 116.5M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CDNA X CDNA CareDx Secondary Managers: Goldman Sachs & Jefferies, Raymond James, BTIG, Craig-Hallum, H.C. Wainwright $93.33 Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CTMX X CTMX CytomX Therapeutics Secondary Managers: JPMorgan, Cowen & Piper Sandler $8.48 Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CYRX X CYRX Cryoport Secondary Managers: Morgan Stanley, Jefferies, SVB Leerink & UBS $76.12 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EDIT X EDIT Editas Medicine Secondary Managers: JPMorgan & Morgan Stanley, Cowen, Credit Suisse $72.11 3.5M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MRUS X MRUS Merus Secondary Managers: Jefferies & SVB Leerink $24.71 Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CYRX X CYRX Cryoport Spot Secondary Managers: Morgan Stanley, Jefferies, SVB Leerink & UBS $ Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INO X INO Inovio Spot Secondary Managers: BofA, Jefferies & Cantor Fitzgerald, Oppenheimer $8.50-9.00 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ONCS X ONCS OncoSec Spot Secondary Managers: BTIG $5.76 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	PAX X PAX Patria IPO Managers: JPMorgan, BofA & Credit Suisse, Goldman Sachs, Bradesco BBI, BTG Pactual, ITAU, Keefe Bruyette, Santander, XP $14.00-16.00 26.65M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AZEK X AZEK Azek Secondary Managers: Barclays, BofA, Goldman Sachs & Jefferies $42.25 17.5M Shares CRSR X CRSR Corsair Gaming Secondary Managers: Goldman Sachs, Barclays, Credit Suisse, Macquarie, Baird, Cowen, & Stifel, Wedbush, Academy Securities $37.73 7.5M Shares DCBO X DCBO Docebo Secondary Managers: Morgan Stanley, Goldman Sachs & Canaccord $70.51 3.65M Shares NVTA X NVTA Invitae Secondary Managers: JPMorgan, Morgan Stanley, Cowen & SVB Leerink $56.93 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PASG X PASG Passage Bio Secondary Managers: JPMorgan, Goldman Sachs & Cowen, Wedbush, Chardan $29.05 7M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SI X SI Silvergate Capital Secondary Managers: Goldman Sachs, Keefe Bruyette & Canaccord, Compass Point, Craig-Hallum $66.43 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

View All Syndicate Announcements »

Exxon Mobil discovers hydrocarbons at Sloanea-1 exploration well

TODAY'S FREE FLY STORIES

Get Full Fly Access